Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.375p -1.35% 100.50p 99.50p 101.50p 101.00p 99.00p 101.00p 25,943.00 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -9.4 -10.4 - 53.40

Silence Therapeutics Share Discussion Threads

Showing 49951 to 49973 of 49975 messages
Chat Pages: 1999  1998  1997  1996  1995  1994  1993  1992  1991  1990  1989  1988  Older
DateSubjectAuthorDiscuss
12/1/2017
16:13
"Success in business can often hinge on opportunities taken (or indeed spurned). Yes, you require a good product, or stellar technology and, of course, decent management. But sometimes company-defining moments come down to happenstance and then having the lead-lined stomach to take the plunge. Silence Therapeutics (LON:SLN) has done just that – taken the plunge - with its US$9.6mln acquisition of an 8.4% stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR). Whether it proves to be a pivotal investment only time will tell. At the very least it looks like a well-timed transaction. Less than six months ago, when Arrowhead was valued at just shy of US$730mln, buying a shareholding of this scale was inconceivable (not mention too expensive). Then fate and poor luck intervened (for Arrowhead at least). In November it cancelled three clinical programmes for drugs designed to tackle liver disease, which caused the stock to tumble to a low of US$1.20 from that August high-point of US$8.22. Silence will have been looking on with interest – not least because the two companies are in the same area of research; they are pioneers in RNA interference (RNAi). This is the cellular process of silencing unwanted or harmful genes. The two companies also use similar delivery mechanisms – GalNAc liver technology - so there ought to be areas where the pair can collaborate. The investment starts the ball rolling in this regard – it is a conversation opener. “Any number of scenarios are possible from mergers, takeovers, cross-collaboration, licensing and at default level maybe nothing,” said Silence’s chief executive Ali Mortazavi. “We have taken a worst case that we are left we with a passive investment.” The UK firm is not alone in having taken a view on Arrowhead and backed that hunch with cold hard cash. The giant Amgen handed over an initial US$56.5mln in September to buy into RNAi therapies being developed to tackle cardiovascular disease as part of a deal worth US$617mln in staged payments. It is worth noting the equity investment at US$7.16 a share provided support for a US$500mln valuation of Arrowhead. Amgen’s interest lies with the firm’s GalNAc technology, which is unaffected by November’s decision. In fact, analysts say the platform has significant untapped potential. If the market has spotted the value still inherent in Arrowhead it has been slow to react. Silence has been far quicker to cotton on. “We are in the field and so are much more knowledgeable about what’s happening,” said Mortazavi. Technologies such as Silence’s and Arrowhead’s are undergoing clinical and preclinical assessment yet the market has assigned both discount valuations. Yet the CRISPR gene editing technology, still very much in its infancy, is receiving billions of dollars of investment cash from big pharma, while listed companies are valued between $500mln and $1bn. This is frustrating for those operating in RNAi, though it is also helped create the “extraordinary circumstances” that allowed Silence to make its move. “A lot of different stars aligned at the same time and Arrowhead fell right back into our zone,” said Mortazavi. “There wasn’t [just] one single reason we did this. At its best this could be a very, very important moment in RNA interference and the ability to actually be able to capture something. “These opportunities don’t come around very often and they may be defining moments.” One should remember Silence is first and foremost a drug development company, not an investment vehicle. “We are going down the development path ourselves. You must not forget this,” said Mortazavi. Indeed, the company continues to use its own IP and know-how to progress its liver-targeted preclinical pipeline. In addition, it is expecting pivotal clinical results from its out-licensed phase III and phase II programmes in mid-2018. The share price, up 4%, suggests the market likes the Arrowhead deal. Equally, investors don’t seem to be getting too carried away. And neither is boss Mortazavi: “We are in a place where any number of things can happen, including nothing.”
callumross
09/1/2017
16:27
A good assesment Callum. This is stage 1 of some type of collaoration. Either way visa vis net cash and SLN's market cap stock price looks £1 wrong price to me. And I don't mean 0!
richie666
09/1/2017
14:32
Makes sense
rogen83
09/1/2017
12:07
Anyway, just topped up with another 1000 shares even though ADVFN is showing it as a sell.
callumross
09/1/2017
12:03
Below is a link as to why SLN are paying so much less for Arrowhead shares than Amgen; http://www.fool.com/investing/2016/11/30/heres-why-arrowhead-pharmaceuticals-inc-is-being-o.aspx Cause is trials abandoned due to FDA liver toxicology issues with their key candidate drugs. Now we know SLN has a new focus on liver at moment. Could this be a way of resurrecting these drug candidates with a SLN delivery mechanism?
callumross
09/1/2017
11:43
Amgen is backing Arrowhead, having bought in at end-September, just before the Arrowhead year-end. Arrowhead paid a lot more than Silence for the shares, paying $7.16 for the 3m shares it bought (price given in Arrowhead 10-K). hTtp://www.fiercebiotech.com/biotech/embargo-lifts-7-30am-et-amgen-strikes-673-5m-cardiovascular-rnai-pact-arrowhead
1gw
09/1/2017
11:16
I've bought some more on the back of that announcement. I think there's a very positive statement on market value from AM in there "We believe that the recent technological advancements in RNA therapeutics have been underestimated and undervalued." Arrowhead stock looks to be up over 20% in the pre-market, so the pyjama traders seem to be viewing this as a precursor to acquisition, but the Arrowhead market cap is quite a bit bigger than Silence's by my calcs, even at Friday's close price. I wonder if Silence are looking to get a licensing deal out of this - i.e. if this is one of the companies that it thinks might need to use one of its patents. If we are headed for consolidation then the Silence stake may end up being bought out by a bigger player who is looking to buy Arrowhead, so there's some option value in there as well.
1gw
09/1/2017
10:45
Two wrong don't make a right in my view. Arrowhead lost $80m last year alone. But who knows.
waterloo01
09/1/2017
10:28
Waterloo - clearly a precursor to a combine between the 2. Universally positive to me.
richie666
09/1/2017
07:23
Does anyone follow this? Beyond saying they have limited confidence in their own platform, what on earth is this about? Back to scatter guns probably. Not one for me.
waterloo01
11/12/2016
23:30
Thanks Rogen8, I guess I can call myself patient after over a decade of holding SRP/SLN. Said a few years back, in the bottom drawer and hopefully one day they'll deliver the goods in this field. Wait on some more it is then.
ukeagle2aus
09/12/2016
23:18
Waterloo posted cautious comments on the SUMM board before the shares doubled. SLN have a good management team and experience board, it's a waiting game
rogen83
09/12/2016
12:38
OMG been a long time since I have been here and still a couple of handles I recognise. I still hold these in the bottom drawer from well before the heady days before I left for down under (9 years ago). Kept a small eye out and really dont know what is going on/outlook etc, but hopefully something will turn up eventually. Good luck all. Eag
ukeagle2aus
30/11/2016
13:53
Thanks for this Waterloo but you could actually look at this as a positive for SLN in that the failure of their delivery mechanism just highlights the proven track record safety profile of SLN's delivery mechanisms.
callumross
30/11/2016
07:56
htTps://endpts.com/hot-on-the-heels-of-a-clinical-hold-arrowhead-torches-its-clinical-pipeline-slashes-staff/
waterloo01
15/11/2016
07:34
'Silence has confirmed the potential of its delivery platform for in vivo gene editing'... looks like a leap forward for Silence. Certainly very good news indeed
gersemi
15/11/2016
07:29
A bit technical for me, but that RNS sounds like good news...
1gw
06/10/2016
17:37
I don't think I'll be running just yet. "Safety problems have not shown up to date in the company's other RNAi drugs, which are all delivered into patients differently from revusiran, Maraganore said. He added that he still expects to have three drugs approved and on the market by 2020." ... but certainly a reminder of the other side of the coin for biotech from the SUMM experience.
1gw
06/10/2016
13:40
hTtps://www.thestreet.com/story/13843510/1/alnylam-gene-silencing-drug-blows-up-damage-could-spread-deep-into-biotech-sector.html Run?
waterloo01
05/10/2016
12:51
Decent volume today. Are we getting a bit of the SUMM slipstream?
1gw
04/10/2016
14:43
Well that's why we buy into biotech I suppose - hoping to get a new treatment through to commercialisation or have someone with deep pockets buy in to help progress a potential treatment. SLN's turn may come... In the meantime it can't do any harm to have a reminder of what can happen.
1gw
04/10/2016
12:28
Looking at todays announcement from SUMM, doesn't it just make you envious. Surely our turn will come!
callumross
29/9/2016
14:46
Canaccord Genuity today reaffirms its buy investment rating on Silence Therapeutics PLC (LON:SLN) and raised its price target to 249p (from 233p).
callumross
Chat Pages: 1999  1998  1997  1996  1995  1994  1993  1992  1991  1990  1989  1988  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170119 19:13:50